Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 11.2% during trading on Thursday . The company traded as low as GBX 3.82 ($0.05) and last traded at GBX 3.82 ($0.05). 13,132,889 shares were traded during trading, a decline of 33% from the average session volume of 19,740,949 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Price Performance
The company has a market capitalization of £16.15 million, a price-to-earnings ratio of -6.57 and a beta of 1.53. The firm’s 50-day simple moving average is GBX 2.67 and its two-hundred day simple moving average is GBX 2.01.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Profitably Trade Stocks at 52-Week Highs
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- 3 REITs to Buy and Hold for the Long Term
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
- There Are Different Types of Stock To Invest In
- CVS Health: Earnings Beat Ignites Stock Rally
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
